Search results for "levodopa"

showing 10 items of 41 documents

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

2005

We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examinatio…

AdultMaleLevodopamedicine.medical_specialtyTime FactorsNeurologyParkinson's diseaseAdministration Oralparkinson's diesease clinical neurophysiology kinematicsKinematicsClinical neurophysiologyAntiparkinson AgentsLevodopaCentral nervous system diseaseBolus (medicine)Internal medicinemedicineHumansAgedbusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseBiomechanical PhenomenaSurgeryNeurologyCarbidopaCardiologyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessPsychomotor Performancemedicine.drug
researchProduct

Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease

2009

BACKGROUND: The neural mechanisms and the circuitry involved in levodopa-induced dyskinesia (LID) are still partially obscure. LID can be considered the consequence of an abnormal pattern or code of activity that originates and is conveyed from the basal ganglia to the thalamus and the cortical motor areas. However, not only striatothalamocortical motor circuits but also other interconnected pathways could be implicated in its pathogenesis. METHODS: In a series of experiments, we applied repetitive transcranial magnetic stimulation (rTMS) over the lateral cerebellum in a group of patients with advanced Parkinson disease, to investigate whether modulation of cerebellothalamocortical circuits…

Dyskinesia Drug-InducedLevodopaCerebellummedicine.medical_treatmentCTBStmSeverity of Illness IndexrehabilitationNOLevodopaNeural PathwaySeverity of Illness Index; Analysis of Variance; Levodopa; Dyskinesia Drug-Induced; Humans; Cerebellum; Aged; Neural Inhibition; Thalamus; Motor Cortex; Parkinson Disease; Evoked Potentials Motor; Neural Pathways; Middle Aged; Neuronal Plasticity; Transcranial Magnetic StimulationThalamusCerebellumNeural PathwaysBasal gangliamedicineHumansEvoked PotentialsThalamuAgedAnalysis of VarianceNeuronal PlasticityDyskinesiaMotor CortexNeural InhibitionParkinson DiseaseMiddle AgedEvoked Potentials MotorTranscranial Magnetic StimulationAged; Analysis of Variance; Cerebellum; Drug-Induced Dyskinesia; Evoked Potentials; Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic StimulationTranscranial magnetic stimulationmedicine.anatomical_structureMotorDyskinesiaDrug-Inducedparkinson's diseaseSettore MED/26 - NeurologiaDrug-Induced DyskinesiaNeurology (clinical)Primary motor cortexmedicine.symptomPsychologyNeuroscienceHumanMotor cortexmedicine.drugNeurology
researchProduct

Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease.

2018

AbstractMotor symptoms are defining traits in the diagnosis of Parkinson’s disease (PD). A crucial component in motor function and control of movements is the integration of efferent signals from the motor network to the peripheral motor system, and afferent proprioceptive sensory feedback. Previous studies have indicated abnormal movement-related cortical oscillatory activity in PD, but the role of the proprioceptive afference on abnormal oscillatory activity in PD has not been elucidated. In the present study, we examine the role of proprioception by studying the cortical processing of proprioceptive stimulation in PD patients, ON/OFF levodopa medication, as compared to that of healthy co…

0301 basic medicineMaleParkinson's diseaselcsh:MedicineStimulationAntiparkinson AgentsLevodopa0302 clinical medicineFeedback SensoryMedicine:Science::Medicine [DRNTU]lcsh:Science0303 health sciencesMultidisciplinarymedicine.diagnostic_testMotor CortexMagnetoencephalographyParkinson DiseaseMiddle Aged3. Good healthProprioceptive functioncortexmedicine.anatomical_structureFemaleMotor cortexmedicine.drugAdultLevodopaParkinsonin tautiSensory systemArticle03 medical and health sciencesmotor cortexMotor systemHumans030304 developmental biologyAgedProprioceptionbusiness.industrylcsh:RMagnetoencephalographyIndex fingermedicine.diseaseProprioceptionaivokuori030104 developmental biologylcsh:QbusinessBeta RhythmNeuroscience030217 neurology & neurosurgeryScientific reports
researchProduct

Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

2000

Abstract The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with l -DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic l -DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic l -DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity ma…

Malemedicine.medical_specialtyLevodopaanimal structuresTyrosine 3-MonooxygenaseReceptors DrugDopamine Agents-DOPANigrostriatal pathwayStriatumBiologySubthalamic nucleusStriatumLevodopaLesionAdrenergic AgentsDopamineInternal medicinemedicineAnimalsRNA MessengerRats WistarOxidopamineReceptors CannabinoidMedial forebrain bundleHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceMedial Forebrain BundleParkinson DiseaseCorpus StriatumRatsmedicine.anatomical_structureEndocrinologynervous systemSettore BIO/14 - Farmacologiamedicine.symptomCannabinoid CB1 receptor mRNA6-Hydroxydopaminemedicine.drugNeuroscience Letters
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Tarantula Hemocyanin Shows Phenoloxidase Activity

1998

An enzyme generally catalyzes one well defined reaction with high specificity and efficiency. We report here in contrast that the copper protein hemocyanin of the tarantula Eurypelma californicum exhibits two different functions. These occur at the same active site. While hemocyanin usually is an oxygen carrier, its function can be transformed totally to monophenoloxidase and o-diphenoloxidase activity after limited proteolysis with trypsin or chymotrypsin. N-acetyldopamine (NADA) is more effectively oxidized than L-dopa or dopamine. This irreversible functional switch of tarantula hemocyanin function is limited to the two subunits b and c of its seven subunit types. A conserved phenylalani…

Models MolecularStereochemistryCopper proteinDopamineProtein subunitmedicine.medical_treatmentPhenylalanineBiochemistrySubstrate SpecificityLevodopaMetalloproteinsMetalloproteinmedicineAnimalsChymotrypsinTrypsinImmunoelectrophoresisMolecular Biologychemistry.chemical_classificationBinding SitesbiologyMonophenol MonooxygenaseActive siteSpidersHemocyaninCell BiologyTrypsinOxygenEnzymeBiochemistrychemistrySpectrophotometryHemocyaninsbiology.proteinElectrophoresis Polyacrylamide GelCoppermedicine.drugJournal of Biological Chemistry
researchProduct

Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

2016

Levodopa (l-DOPA) is the most effective pharmacologic agent in Parkinson's disease and remains the "gold standard". Nevertheless, in long-term treatments, dyskinesias and motor complications can emerge. In this work, the combined use of l-DOPA methylester hydrochloride prodrug (LDME) with transbuccal drug delivery was supposed as a good alternative method to optimize the bioavailability of l-DOPA, to maintain constant plasma levels and to decrease the drug unwanted effects. The effects of environmental pH on buccal delivery of LDME were evaluated ex vivo. The increase of pH value from 5.8 to 6.2 implies an improvement of drug permeation. Since the pH increase causes the raising of hydrolyti…

DrugHydrochloridemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacologyAntiparkinson AgentsLevodopachemical stability03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineDrug StabilitySettore MED/28 - Malattie OdontostomatologicheProdrugsmedia_commonBuccal permeationMouthintellidrug deviceMouth MucosaParkinson DiseaseGeneral MedicineBuccal administrationPermeationProdrug021001 nanoscience & nanotechnologytransmucosal drug deliveryBioavailabilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryprodrug0210 nano-technology030217 neurology & neurosurgeryEx vivo
researchProduct

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induct…

2002

Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the d…

MaleDyskinesia Drug-Inducedmedicine.medical_specialtyIndolesCaudate nucleusStriatumIndirect pathway of movementAntiparkinson AgentsLevodopachemistry.chemical_compoundDopamine Uptake InhibitorsParkinsonian DisordersTachykininsInternal medicineNeural PathwaysmedicineAnimalsheterocyclic compoundsRNA MessengerProtein PrecursorsBromocriptineGeneral NeuroscienceMPTPPutamenNeuropeptidesReceptors Purinergic P1CallithrixEnkephalinsMazindoldopamine agonists peptide mRNAs L-DOPA 1-methyl-4-phenyl-1236-tetrahydropyridine primates dyskinesiaBromocriptinenervous system diseasesNeostriatumRopiniroleEndocrinologynervous systemchemistryDyskinesiaSettore BIO/14 - FarmacologiaFemalemedicine.symptommedicine.drugNeuroscience
researchProduct

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct

Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa

2020

Levodopamedicine.medical_specialtyHyperactivationbusiness.industryDermatologyGeneral MedicineDiseasemedicine.diseaseDermatologyAcral lentiginous melanomaPathology and Forensic Medicinemedicinebusinessmedicine.drugThe American Journal of Dermatopathology
researchProduct